Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 3)
Vascular Disease, Heart Disease
About this trial
This is an interventional basic science trial for Vascular Disease focused on measuring Urocortin 2, Urocortin 3, Nitric Oxide, Plethysmography, Forearm blood flow, Vascular, Heart failure, endothelium, Cyclo-oxygenase pathway, EDHF
Eligibility Criteria
Inclusion Criteria:
- Healthy male volunteers between 18 - 65 years (inclusive)
Exclusion Criteria:
- Lack of informed consent- Age <18 years > 65 years
- Current involvement in a clinical trial
- Severe or significant co-morbidity including bleeding diathesis, renal or hepatic failure
- Smoker
- History of anaemia
- Recent infective/inflammatory condition
- Recent blood donation (prior 3 months)
- Positive baseline urine test for drugs of abuse (including cannabinoids, benzodiazepines, opiates, cocaine and amphetamines)
- History of allergy to Aspirin
Sites / Locations
- Wellcome Trust Clinical Research Facility, Royal Infirmary of Edinburgh
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Placebo Comparator
Experimental
Experimental
Experimental
Nitric Oxide Clamp
Saline Placebo
Fluconazole
Aspirin
Combined
Forearm blood flow response to Urocortins 2, 3 and Substance P in the presence of Nitric Oxide clamp
Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of saline placebo.
Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of intra-arterial Fluconazole.
Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of cyclooxygenase inhibition with Aspirin.
Forearm blood flow response to Urocortin 2, Urocortin 3 and Substance P in the presence of inhibition of cycloxygenase, EDHF and NO pathways with Aspirin, Fluconazole and NO clamp.